Today: 25 June 2026
Browse Category

NASDAQ:EDIT 2 November 2025 - 4 June 2026

CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics shares soared 11.7% to $58.15 after presenting at the Jefferies Global Healthcare Conference, with sector momentum lifting gene-editing stocks and the SPDR S&P Biotech ETF up 3.0%. Casgevy, its key sickle cell therapy, posted $43 million Q1 revenue, but a $122.9 million net loss and biotech risks mean the rally hinges on investor appetite and upcoming clinical updates.
4 June 2026
·······
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics shares fell 4.3% to $54.00 after a filing showed CFO Raju Prasad exercised and sold 29,700 shares under a preset trading plan. The move comes ahead of the company’s Jan. 12 slot at the J.P. Morgan Healthcare Conference and an expected mid-February earnings report. Gene-editing peers also traded lower. CASGEVY revenue and rollout remain key investor focus.
9 January 2026
·······
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics shares closed down 1.4% at $52.44 on Dec. 31, the final trading day of 2025. U.S. markets were shut Jan. 1 for New Year’s. Investors are watching for early-2026 updates on Casgevy’s rollout and the next earnings schedule as trading resumes Jan. 2. Biotech ETFs were little changed in light year-end trading.
2 January 2026
······
Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

The FDA will announce a new fast-track approval process for personalized gene-editing therapies in early November, sending CRISPR Therapeutics shares up 8% and Editas up 12%. CRSP reported over 90% mRNA correction in preclinical CTX460 data and will present Phase 1 CTX310 results at the AHA conference Nov. 8. Intellia paused a TTR amyloidosis trial after a liver injury, causing its stock to fall 46%.
2 November 2025
······

Stock Market Updates

Micron, Qualcomm lift chip stocks after hours as Nasdaq slips

Micron, Qualcomm lift chip stocks after hours as Nasdaq slips

25 June 2026
Micron soared 16.34% after hours as customers locked in nearly $100 billion in future supply obligations—about 2.4 times its latest quarterly revenue—fueling a $400 billion surge in chip stocks and reversing the tech selloff that erased over $1 trillion from the Nasdaq 100 this week.
Western Digital falls after AI-storage rally, investors look to Micron

Western Digital falls after AI-storage rally, investors look to Micron

25 June 2026
Western Digital (NASDAQ:WDC) shares dropped about 4% after a multi-week rally fueled by AI storage demand, as investors awaited Micron Technology’s earnings for new signals on enterprise storage spending; analysts cite a persistent hard-disk supply deficit that could support pricing into 2027, with Morgan Stanley raising its price target to $650.
BlackBerry falls with volume outpacing buyback plan ahead of earnings

BlackBerry falls with volume outpacing buyback plan ahead of earnings

25 June 2026
BlackBerry closed down 2.3% at $8.62 despite Stifel initiating coverage with a Buy and $12 target—39% above the close—while trading volume of 38.3 million shares far exceeded its entire buyback authorization, highlighting investor focus ahead of Thursday’s Q1 results and underscoring the limited impact of BlackBerry’s capital return plan.
Opendoor slides after landing in Russell 3000, liquidity and dilution concerns follow

Opendoor edges up before Russell 3000 move, soft housing numbers weigh

25 June 2026
Santos shares closed down 0.96% at A$7.24 after Brent crude slumped US$3.34 to US$73.74, cutting potential annual gross sales from its new Pikka project by about US$50 million at plateau rates; Pikka’s ramp to 80,000 barrels per day is key, as oil price swings now have a direct impact on Santos’ production-linked revenue and its US$2.5 billion net debt reduction target.
Go toTop